{"id":"NCT01362530","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)","officialTitle":"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-09-13","primaryCompletion":"2013-03-14","completion":"2013-08-16","firstPosted":"2011-05-30","resultsPosted":"2014-04-04","lastUpdate":"2018-09-25"},"enrollment":307,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Chemotherapy Induced Nausea and Vomiting"],"interventions":[{"type":"DRUG","name":"Aprepitant 125 mg","otherNames":["MK-0869, Emend®"]},{"type":"DRUG","name":"Aprepitant 80 mg","otherNames":["MK-0869, Emend®"]},{"type":"DRUG","name":"Aprepitant powder for suspension (PFS)","otherNames":["MK-0869, Emend®"]},{"type":"DRUG","name":"Ondansetron","otherNames":["Zofran™"]},{"type":"DRUG","name":"Placebo for Aprepitant 125 mg","otherNames":[]},{"type":"DRUG","name":"Placebo for Aprepitant 80 mg","otherNames":[]},{"type":"DRUG","name":"Placebo for Aprepitant PFS","otherNames":[]},{"type":"DRUG","name":"Emetogenic chemotherapy","otherNames":[]}],"arms":[{"label":"Aprepitant Regimen","type":"EXPERIMENTAL"},{"label":"Control Regimen","type":"PLACEBO_COMPARATOR"}],"summary":"This study will compare the safety and efficacy of a three-day oral aprepitant regimen (aprepitant plus ondansetron) to ondansetron alone in the prevention of chemotherapy-induced nausea and vomiting (CINV) in the 120 hours following the initiation of chemotherapy in pediatric participants. Those who complete this first cycle of treatment and meet certain eligibility criteria will have the option of continuing for 5 additional cycles of open-label aprepitant.","primaryOutcome":{"measure":"Percentage of Participants With a Complete Response in the Delayed Phase of Cycle 1","timeFrame":"25 to 120 hours after the start of chemotherapy","effectByArm":[{"arm":"Aprepitant Regimen","deltaMin":50.7,"sd":null},{"arm":"Control Regimen","deltaMin":26,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.01"}]},"eligibility":{"minAge":"6 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":12},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["25770814","29893452"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":46,"n":152},"commonTop":["Anaemia","Vomiiting","Neutropenia","Nausea","Thrombocytopenia"]}}